Veerhealth Care Limited FY26 Results

FY26 Net Profit: ₹0.54 crore | FY26 Total Income: ₹33.29 crore

Reader Takeaway: Strong revenue growth but margin pressure persists. Need to watch execution of ambitious FY27 targets.

What just happened

Veerhealth Care Limited reported its financial results for the fiscal year ended March 31, 2026 (FY26). The company posted a total income of ₹33.29 crore, marking a significant year-over-year increase of 86.08%. Net profit for the year stood at ₹0.54 crore, showing a 38.46% rise compared to the previous fiscal year. EBITDA was ₹3.27 crore.

Why this matters

The strong revenue growth indicates expanding market reach. However, a decline in both EBITDA and net profit margins highlights cost pressures. Investors will be keen to see if the company can improve profitability as it scales.

The backstory

Veerhealth Care's performance in FY26 was influenced by both operational expansion and some non-recurring financial events. Q4FY26 profitability was impacted by a ₹0.31 crore forex loss and a ₹0.49 crore provision for deferred tax. Management stated these are not expected to recur in FY27.

What changes now

The company has set ambitious targets for FY27, projecting total revenue between ₹70-75 crore with a net profit margin of 7-10%. They also aim for ₹100 crore in revenue with a 10% net profit margin within 24 months. This signals a focus on aggressive expansion.

Risks to watch

Key concerns include the ongoing margin compression, despite revenue scaling. The aggressive FY27 revenue target of doubling last year's topline presents significant execution risk. Investors need to monitor cost management alongside growth.

Peer comparison

(No peer comparison data was provided in the filing.)

Context metrics (time-bound)

EBITDA margin for FY26 was 9.82%, down 18 basis points year-over-year. Net profit margin was 1.62%, down 56 basis points year-over-year. Key orders include ₹10.08 crore from an FMCG company, ₹3.28 crore from the domestic market, ₹1.76 crore from a domestic pharmacy chain, and ₹1.39 crore from USA exports.

What to track next

Investors should closely watch Veerhealth Care's ability to manage expenses and improve its profit margins while pursuing its aggressive revenue growth targets for FY27. The company’s success in securing USFDA plant clearance is a positive operational development to monitor.